NCT01206504No Longer Available不适用
Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- MacroGenics
研究概览
简要总结
This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.
详细描述
The objective of this study is to provide expanded access to MGAWN1; the study is not intended for subjects who are eligible for and have access to non-expanded access protocols.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 8 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For West Nile Neuroinvasive Disease subjects: Have neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis
- •For immunocompromised subjects with suspected West Nile virus infection:
- •Receiving immunosuppressive treatment for any disease, such as autoimmune diseases, or transplant recipients; or
- •Have received organs or tissues or cells from donors likely infected with West Nile virus (as shown by serology or PCR/NAT from the donor, organs, or tissues) or
- •Have acquired immunodeficiency (other than from immunosuppressive treatment or from receiving infected transplants) or congenital immunodeficiency
- •For subjects with substantial exposure to West Nile virus: Exposure by any route, including percutaneous, inhalation, or mucosal exposure (such as might occur in a laboratory accident)
- •Develop signs and/or symptoms within 14 days before study enrollment
排除标准
- 未提供
研究者
相似试验
终止
2 期
Treatment of West Nile Virus With MGAWN1West Nile Neuroinvasive DiseaseWest Nile Virus InfectionAcute Flaccid ParalysisEncephalitisWest Nile FeverMeningitisNCT00927953MacroGenics13
已完成
1 期
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy AdultsWest Nile FeverNCT00537147National Institute of Allergy and Infectious Diseases (NIAID)26
已完成
1 期
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy AdultsWest Nile Fever EncephalitisNCT00094718National Institute of Allergy and Infectious Diseases (NIAID)56
招募中
2 期
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone LymphomaExtranodal Marginal Zone LymphomaNCT06569680Izidore Lossos, MD35
已完成
1 期
Vaccine to Prevent West Nile Virus DiseaseHealthyWest Nile FeverHealthy VolunteerHVNCT00106769National Institute of Allergy and Infectious Diseases (NIAID)15